Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT
Standard
Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT. / Spyridonidis, Alexandros; Labopin, Myriam; Brissot, Eolia; Moiseev, Ivan; Cornelissen, Jan; Choi, Goda; Ciceri, Fabio; Vydra, Jan; Reményi, Péter; Rovira, Montserrat; Meijer, Ellen; Labussière-Wallet, Hélène; Blaise, Didier; van Gorkom, Gwendolyn; Kröger, Nicolaus; Koc, Yener; Giebel, Sebastian; Bazarbachi, Ali; Savani, Bipin; Nagler, Arnon; Mohty, Mohamad.
In: BONE MARROW TRANSPL, Vol. 57, No. 12, 12.2022, p. 1774-1780.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT
AU - Spyridonidis, Alexandros
AU - Labopin, Myriam
AU - Brissot, Eolia
AU - Moiseev, Ivan
AU - Cornelissen, Jan
AU - Choi, Goda
AU - Ciceri, Fabio
AU - Vydra, Jan
AU - Reményi, Péter
AU - Rovira, Montserrat
AU - Meijer, Ellen
AU - Labussière-Wallet, Hélène
AU - Blaise, Didier
AU - van Gorkom, Gwendolyn
AU - Kröger, Nicolaus
AU - Koc, Yener
AU - Giebel, Sebastian
AU - Bazarbachi, Ali
AU - Savani, Bipin
AU - Nagler, Arnon
AU - Mohty, Mohamad
N1 - © 2022. The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/12
Y1 - 2022/12
N2 - In this registry-based study which includes acute myeloid leukemia patients who underwent a matched unrelated donor allogeneic peripheral-blood stem cell transplantation in complete remission and received post-transplant cyclophosphamide (PTCY) as graft-versus-host disease (GvHD) prophylaxis, we compared 421 recipients without anti-thymocyte globulin (ATG) with 151 patients with ATG. The only significant differences between PTCY and PTCY + ATG cohorts were the median year of transplant and the follow-up period (2017 vs 2015 and 19.6 vs 31.1 months, respectively, p < 0.0001). Overall, 2-year survival was 69.9% vs 67.1% in PTCY and PTCY + ATG, respectively, with deaths related to relapse (39% vs 43.5%), infection (21.9% vs 23.9%) or GvHD (17.1% vs 17.4%) not differing between groups. On univariate comparison, a significantly lower rate of extensive chronic GvHD was found when ATG was added (9.9% vs 21%, p = 0.029), a finding which was not confirmed in the multivariate analysis. The Cox-model showed no difference between PTCY + ATG and PTCY alone with respect to acute and chronic GvHD of all grades, non-relapse mortality, relapse, leukemia-free survival, overall survival, and GvHD-free-relapse-free survival between study cohorts. Our results highlight that the addition of ATG in PTCY does not provide any extra benefit in terms of further GvHD reduction, better GRFS or better survival.
AB - In this registry-based study which includes acute myeloid leukemia patients who underwent a matched unrelated donor allogeneic peripheral-blood stem cell transplantation in complete remission and received post-transplant cyclophosphamide (PTCY) as graft-versus-host disease (GvHD) prophylaxis, we compared 421 recipients without anti-thymocyte globulin (ATG) with 151 patients with ATG. The only significant differences between PTCY and PTCY + ATG cohorts were the median year of transplant and the follow-up period (2017 vs 2015 and 19.6 vs 31.1 months, respectively, p < 0.0001). Overall, 2-year survival was 69.9% vs 67.1% in PTCY and PTCY + ATG, respectively, with deaths related to relapse (39% vs 43.5%), infection (21.9% vs 23.9%) or GvHD (17.1% vs 17.4%) not differing between groups. On univariate comparison, a significantly lower rate of extensive chronic GvHD was found when ATG was added (9.9% vs 21%, p = 0.029), a finding which was not confirmed in the multivariate analysis. The Cox-model showed no difference between PTCY + ATG and PTCY alone with respect to acute and chronic GvHD of all grades, non-relapse mortality, relapse, leukemia-free survival, overall survival, and GvHD-free-relapse-free survival between study cohorts. Our results highlight that the addition of ATG in PTCY does not provide any extra benefit in terms of further GvHD reduction, better GRFS or better survival.
KW - Humans
KW - Antilymphocyte Serum/therapeutic use
KW - Peripheral Blood Stem Cell Transplantation/methods
KW - Unrelated Donors
KW - Graft vs Host Disease
KW - Cyclophosphamide/therapeutic use
KW - Hematopoietic Stem Cell Transplantation/methods
KW - Leukemia, Myeloid, Acute/drug therapy
KW - Recurrence
KW - Retrospective Studies
U2 - 10.1038/s41409-022-01816-1
DO - 10.1038/s41409-022-01816-1
M3 - SCORING: Journal article
C2 - 36071114
VL - 57
SP - 1774
EP - 1780
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 12
ER -